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Severe Osteomyelitis as a Complication of Tokyo-172 BCG 
Vaccination 
The bacilli Calmette-Guérin (BCG) Tokyo-172 strain was considered to exhibit good 
protective efficacy with a low rate of unfavorable side effects. However, we describe a rare 
case of BCG osteomyelitis developed in an immunocompetent host who was given with 
BCG Tokyo-172 vaccine on the left upper arm by multipuncture method. A 9-month-old 
girl presented with progressive inability to move her right elbow and had radiographic 
evidence of septic elbow combined with osteomyelitis of right distal humerus. A biopsy 
from the site revealed chronic caseating granulomatous inflammation, positive for BCG 
Tokyo-172 strain on the multiplex polymerase chain reaction. The child had to undergo 
second surgical debridements and oral antituberculosis chemotherapy. There were no 
sequelae after 2 yr of follow-up. This complication, although uncommon, should be 
considered in the appropriate clinical setting.
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CASE REPORT
Pediatrics
INTRODUCTION
Tokyo-172 BCG vaccine has been admitted by the quality con-
trol of World Health Organization (WHO) and reported to have 
a lower residual virulence and less reactogenicity. The vaccine 
was considered to exhibit favorable characteristics with regard 
to both efficacy and side reactions (1). Nevertheless, there were 
some severe adverse reactions that developed beyond vaccina-
tion site and regional ipsilateral axillary lymph-nodes. The risk 
of severe adverse reactions was high among those of primary 
immunodeficiency. Osteomyelitis is a very rare but serious late 
complication of BCG-immunization in immunocompetent in-
dividuals and results from generalized dissemination of BCG (2).
  Here, we report a rare case of BCG osteomyelitis of the elbow 
in a 9-month-old girl who had no underlying immunodeficien-
cy disorders.
CASE DESCRIPTION
A 9-month-old Korean girl was referred to our clinic because of 
a progressive inability to move her right elbow on January 9, 
2007. Approximately 3 weeks ago, the child was seen by a local 
orthopedic physician. The parents had noted that she was re-
luctant to move her right arm through complete ranges. Also, 
the patient would cry when the arm was abducted. At that time, 
the doctor of the local clinic had an initial diagnosis of a pulled 
elbow, in which the arm was reducted and put into an arm cast. 
Three days later, painful swelling in her right elbow developed 
with the limitation in active movement and inability to rotate. 
  The patient was born by normal vaginal delivery with normal 
Apgar score. She was vaccinated with Tokyo-172 BCG on the 
left upper arm at one month of age. BCG vaccine was adminis-
tered percutaneously by multipuncture method. She had re-
ceived routine immunizations up to date including hepatitis B, 
diphtheria-tetanus-pertussis (DTaP), polio (IPV) in accordance 
with the national vaccination program guidelines. She lived in 
Ansan and had no history of farm or zoo visit. The patient had no 
previous history of illness and no known familial tuberculosis 
history. Physical examination revealed  obvious swelling, ery-
thema, tenderness in the area of the right elbow. Furthermore, 
the range of elbow movement was restricted. Other physical 
examinations were normal.
  The laboratory results at admission revealed the erythrocyte 
sedimentation rate 107 mm/hr and C-reactive protein (CRP) 
1+. Radiological studies suggested the lesion in the elbow. Also, 
MRI revealed contrast enhancement in and around the right 
elbow, compatible with septic elbow. Signal change and con-
trast enhancement in the epiphysis and metaphysis of right dis-
tal humerus were noted. These features suggested septic elbow 
combined with osteomyelitis. No other significant abnormal Kwon HJ, et al.  •  Osteomyelitis by BCG vaccination
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finding was shown in other skeletal areas.
  Initially, septic elbow was diagnosed and surgery was per-
formed to treat osteomyelitis of right elbow and revealed con-
centrated dirty granulation tissue in the elbow joint space that 
was removed. After operation, the child had been treated with 
ampicillin/sulbactam before the proper diagnosis had been es-
tablished. Since the osteomyelitis lesion was refractory with an-
tibiotic therapy, we considered mycobacterium as the patho-
gen. A lesion biopsy specimen was sent to the pathology de-
partment. Histopathological examination of the biopsy speci-
men revealed a chronic caseating granulomatous inflammatory 
reaction. Microscopic examination of the pus with Ziehl-Neelsen 
staining showed no Acid-fast bacilli but a culture of the biopsy 
was identified with Mycobacterium tuberculosis. As the postop-
erative diagnosis was osteomyelitis of M. tuberculosis, we started 
treatment with regimen of rifampin, isoniazid and pyrazinamide. 
Following the culture report, the sensitivity test showed that the 
strain was resistant to pyrazinamide. This sensitivity study was a 
distinguishing characteristic of M. bovis. Therefore, we requested 
multiplex polymerase chain reaction (PCR) for the Mycobacte-
rium complex colony to differentiate the pathogen. A mycobac-
terium culture of the biopsy sample later revealed to have an 
identical amplification with the BCG Tokyo-172 strain on the 
multiplex PCR for the Mycobacterium complex colony (Fig. 1). 
Based on these findings, the diagnosis of osteomyelitis due to 
Tokyo-172 BCG vaccination was confirmed.
  Immunological investigation for the evaluation of cellular and 
humoral immunity was performed, including complement 
CH50, C3, and C4, immunoglobulins and intracellular oxida-
tion (dihydrorhodamine) and revealed normal findings. There-
fore, immunodeficiency disorders were ruled out. In addition, 
an evaluation for extrapulmonary TB was negative. 
  The patient had been treated with a regimen consisting of   
rifampin (10 mg/kg body weight per day), isoniazid (10 mg/kg 
body weight per day) and pyrazinamide (25 mg/kg body weight 
per day) as an outpatient. However, after two months of treat-
ment, MRI showed no interval change (Fig. 2). We added strep-
tomycin (30 mg/kg body weight per day intramuscularly for       
10 days) and ethambutol (15 mg/kg body weight per day) in-
stead of pyrazinamide due to the sensitivity result. Pyrazinamide 
was eliminated because of it is generally considered ineffective 
for the treatment of BCG osteomyelitis. Following the change of 
regimen, debridement and curettage was again performed four 
months after the first surgery. The planned chemotherapy regi-
men was continued during 12 months. She has been followed up 
for 2 yr and has remained without signs of growth disturbances 
or impairment of function in adjacent joints. The function of the 
right arm was normal in terms of range of motion and activity. 
The most recent radiological examination showed the decrease 
of geographic osteolytic lesion on the distal humerus and peri-
osteal reaction, disappearance of neighboring soft tissue swell-
ing, which suggested improving state of osteomyelitis and arthri-
tis. The patient recovered without complications.
DISCUSSION
The prevalence of tuberculosis in Korea was higher than in oth-
er OECD countries. Subsequently, BCG vaccination emerged 
as a national policy for the control of tuberculosis. In Korea, 
95%-99% of children are vaccinated with BCG within the first 
month of life. Two types of BCG vaccine are currently used in 
Korea. The usage of all freeze-dried BCG vaccine (Danish 1331, 
Denmark, Statens Serum Institue) was approved officially on 
the National Immunization Program guidelines. The Tokyo-172 
BCG also has been used for the last 15 yr.
  In recent years, unfortunately, unfavorable adverse reactions 
of BCG vaccination were occasionally documented. The most 
serious side effect is generalized BCG infection. Bone and joint 
tuberculosis after BCG vaccination has been described mostly 
by Scandinavian authors (3-5). Hematogenous spread of BCG 
may result in osteomyelitis, but this is a rare complication. The 
incidence rate of BCG osteomyelitis was reported to be 1.11 
Fig. 2. Magnetic resonance image showing a high signal intensity and enhancement 
in head of proximal radius. Synovial hypertrophy and fluid collection in elbow joint.
Fig. 1. The detection of BCG substrain using the multiplex polymerase chain reaction. 
The sample of this patient shows an identical amplification with the Mycobacterium 
bovis BCG Tokyo-172 strain. M, marker; N, negative; MTB, M. tuberculosis; Pasteur, 
M. bovis BCG Pasteur; Tokyo, M. bovis BCG Tokyo-172.
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cases in a million in Europe (5, 6). Since then, only rare cases of 
BCG osteomyelitis have been reported in Asia (7-9). The inci-
dence and type of complication with BCG vaccination depend 
on the strain and administration modalities, but no single cause 
has been defined (10). 
  It has been shown that the BCG Tokyo-172 strain exhibits 
good protective efficacy with a low rate of unfavorable side ef-
fects (1, 11, 12). The WHO Expert Committee on Biological Stan-
dardization determined the formulation of international re-
quirements for manufacture and control of BCG vaccine (1). 
The Tokyo-172 BCG vaccine met the requirements and had a 
good safety record. So some pediatric practitioners in Korea use 
BCG Tokyo-172 vaccine with paying the expensive price partic-
ularly because of expecting a low rate of complications. Howev-
er, a systemic review of adverse reactions has not been estab-
lished in Korea as in Japan and in Taiwan (13, 14).
  As we describe a rare case of osteomyelitis as a complication 
of BCG Tokyo-172 vaccine, it shows that the severe side effect 
can be associated with the Tokyo-172 strain. According to the 
previous reported cases, the lesion tended to appear on the 
same side of the body as the vaccination. In our patient, the he-
matogenous spread is the likely cause as the lesion is located on 
the opposite side of the injection site (in the left deltoid region). 
And the lesion did not improve sufficiently with an initial treat-
ment by surgical debridement and oral antituberculosis che-
motherapy, including the use of isoniazid and rifampicin, al-
though the Tokyo-172 strain isolated from the lesion was sus-
ceptible to isoniazid and rifampicin. This indicated that our pa-
tient had refractory BCG osteomyelitis. 
  In terms of efficacy, no consensus exists as to which strains 
of BCG is the best for general use. The benefit with Tokyo-172 
BCG vaccine has been shown; however, few studies have dem-
onstrated the occurrence of severe adverse effect with this strain 
in Korea. To date, only 2 other cases of BCG Tokyo-172 related 
osteomylitis have been reported in Korea (15). New assessment 
and comparison are required to address the challenges raised 
by the Tokyo 172 strain in particular. The follow-up of BCG com-
plications is an essential task of BCG vaccination program. 
  We learned that clinicians should consider BCG osteomyeli-
tis when the BCG vaccinated child presenting tuberculous os-
teomyelitis. Most BCG osteomyelitis shows favorable prognosis 
with oral antituberculsosis chemotherapy or surgical debride-
ment and oral antituberculsosis chemotherapy. However, our 
case had to undergo second operation despite the oral antitu-
berculosis chemotherapy due to initial mistaken-diagnosis. It is 
difficult to distinguish BCG osteomyelitis, because it is very rare 
disease with a long latent period between the vaccination and 
the onset of symptoms. The clinical presentation of BCG osteo-
myelitis is non-specific and radiographic findings are also not 
extraordinary. Without considering this condition, the diagno-
sis and treatment can be delayed as in the case of our patient. 
Moreover, culture is time-consuming, resulting in a delay in the 
initiation of the specific treatment. Recently, multiplex PCR 
method have been utilized and proved to be a rapid and reliable 
method (16-18). The detection of BCG substrains using the 
multiplex PCR allowed us to differentiate BCG Tokyo-172 os-
teomyelitis from other mycobacterial infections. 
  As this case report demonstrates, BCG Tokyo-172 vaccine 
may be complicated by hematogenous spread to the bone. A 
high-index of suspicion of BCG-related osteomylitis is crucial, 
and confirmation of the pathogen can be helpful with using of 
PCR.
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